Leveraging mature hepatic targeting strategies and optimized oligonucleotide modification systems, Youngen’s liver-targeted delivery pipelines enable efficient, stable, and high-specificity accumulation of RNAi therapeutics in hepatocytes with a favorable safety profile. Differentiated from conventional single-target therapies, our metabolic pipelines adopt a dual-target therapeutic strategy, simultaneously intervening in core pathogenic genes and key metabolic signaling pathways that drive lipid overaccumulation, glucose metabolic disorder. We aim to provide novel and potent RNAi therapeutic solutions for refractory obesity and chronic metabolic diseases.
Medication for nervous system disorders, including but not limited to conditions such as anxiety, depression, epilepsy, and neurodegenerative diseases like Parkinson's and Alzheimer's
If you want to know more about central nervous system fatigue treatment, please visit our website.
Youngen, based in Beijing, is a leading oligonucleotide therapeutic company built around AOC modality. Youngen has been dedicated to develop RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-classband Best-in-class potentials.We are advancing programs across key therapeutic areas, including cardiovascular, renal, central nervous system (CNS), and metabolic diseases, to deliver novel treatment options for patients in need.
Cardiovascular therapy, encompassing a comprehensive range of pharmacological interventions, surgical procedures, and lifestyle modifications designed to prevent, manage, and treat diseases of the heart and blood vessels.
You must be logged in to post a comment.